- Home
- PHAR vs BHRB Comparison
PHAR vs BHRB Comparison
Compare PHAR & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BHRB
- Stock Information
- Founded
- PHAR 1988
- BHRB 1852
- Country
- PHAR Netherlands
- BHRB United States
- Employees
- PHAR N/A
- BHRB N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BHRB Major Banks
- Sector
- PHAR Health Care
- BHRB Finance
- Exchange
- PHAR Nasdaq
- BHRB Nasdaq
- Market Cap
- PHAR 951.7M
- BHRB 907.7M
- IPO Year
- PHAR N/A
- BHRB N/A
- Fundamental
- Price
- PHAR $17.07
- BHRB $65.46
- Analyst Decision
- PHAR Strong Buy
- BHRB Strong Buy
- Analyst Count
- PHAR 3
- BHRB 3
- Target Price
- PHAR $30.00
- BHRB $71.67
- AVG Volume (30 Days)
- PHAR 19.8K
- BHRB 45.6K
- Earning Date
- PHAR 11-06-2025
- BHRB 10-23-2025
- Dividend Yield
- PHAR N/A
- BHRB 3.37%
- EPS Growth
- PHAR N/A
- BHRB 264.64
- EPS
- PHAR 0.00
- BHRB 7.05
- Revenue
- PHAR $362,274,000.00
- BHRB $331,643,000.00
- Revenue This Year
- PHAR $17.70
- BHRB $51.05
- Revenue Next Year
- PHAR $12.25
- BHRB $5.90
- P/E Ratio
- PHAR $3,068.84
- BHRB $9.24
- Revenue Growth
- PHAR 26.78
- BHRB 82.85
- 52 Week Low
- PHAR $7.35
- BHRB $47.57
- 52 Week High
- PHAR $17.76
- BHRB $72.68
- Technical
- Relative Strength Index (RSI)
- PHAR 60.37
- BHRB 67.29
- Support Level
- PHAR $15.81
- BHRB $59.00
- Resistance Level
- PHAR $17.50
- BHRB $61.90
- Average True Range (ATR)
- PHAR 0.91
- BHRB 1.65
- MACD
- PHAR 0.09
- BHRB 0.44
- Stochastic Oscillator
- PHAR 80.47
- BHRB 93.41
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.